Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
Stocks in this Quantisnow insightHealth Care
Historical context for PFE
Across the 25 sessions after earlier PFE headlines, the stock closed higher 8 times and lower 17 times, with a median move of 0.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PFE | SPY |
|---|---|---|---|
| May 13, 2026 | European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors | +0.3% | +0.6% |
| May 5, 2026 | Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance | +0.6% | +0.8% |
| Apr 29, 2026 | Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma | -0.8% | -0.0% |
| Apr 28, 2026 | Pfizer Reaches Three Settlement Agreements for VYNDAMAX | -1.2% | -0.5% |
| Apr 23, 2026 | Pfizer Declares Second-Quarter 2026 Dividend | -0.5% | -0.4% |
| Apr 21, 2026 | Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026 | -0.8% | -0.7% |
Quantisnow market dataNYSE
PFE
Pfizer Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for PFE
Full PFE profile on Quantisnow Follow PFE and get a push notification the moment its next story breaks.